Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can brain scans and gut bacteria reveal Alzheimer's secrets?

NCT ID NCT07118137

Knowledge-focused Sponsor: Norwegian University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study aims to understand why people with Alzheimer's disease differ from each other and from healthy older adults. Researchers will use advanced brain imaging (7T MRI), brain wave recordings (EEG), and blood and stool samples to look for patterns that might reflect different disease mechanisms. They will also track people with mild cognitive impairment to see if early markers can predict who later develops Alzheimer's. The goal is to improve early diagnosis and tailor future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multimodal assessment including 7T MRI, EEG, blood and stool sample analysis, and neuropsychological tests
What this could lead to
Could help identify subtypes of Alzheimer's disease and early markers that predict who will progress from mild cognitive impairment to dementia, improving early diagnosis and personalized care.
What could go wrong
This is an observational study with a small number of participants, so findings may not apply to everyone. It is exploratory and will not directly test a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants will be recruited from the region of Trøndelag, Norway. The study population will include individuals with cognitive symptoms as well as cognitively healthy, age- and sex-matched controls. Recruitment will take place through memory clinics and primary care services. All participants will undergo standardized assessments and data collection as specified in the study protocol.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis based on current ICD criteria for AD or MCI . * \>55years. * Norwegian native speaker * Lives at home and not in a health institution Exclusion Criteria: * Patients with severe cognitive impairment that prevents assessment with the selected modalities (planned cut-off: CDR \> 2). * Presence of brain tumors. * History of traumatic brain injury. * History of cranial surgery. * Contraindications to the selected imaging modalities (e.g., 7T MRI or EEG). * Diagnosis of other neurodegenerative diseases such as Parkinson's disease or ALS. 7T MRI contraindications: * Large tattoos close to the head region, permanent makeup or unremoveable piercings * Certain models of pacemakers (if pacemaker implantet, MRI physicist at 7T-lab will be conferred) * Implantet metal in body (clips, stents, prothesis, skrews, plates, teeth etc.)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease Memory Disorders neurodegenerative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Magnetic resonance imaging Memory impairment Neurodegenerative diseases

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Norwegian University of Sciene and Technology / Norges teknisk-naturvitenskapelige universitet (NTNU)

    RECRUITING

    Trondheim, Trønderlag, 7030, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.